Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Description

This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC). The aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810). The first part of the study tested several different doses of cemiplimab given weekly for 12 weeks. The study is also looking at several other research questions, including: * What side effects may happen from taking the study drug * To see effect of cemiplimab on the tumor * How much study drug is in the blood at different times

Conditions

Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma

Study Overview

Study Details

Study overview

This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC). The aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810). The first part of the study tested several different doses of cemiplimab given weekly for 12 weeks. The study is also looking at several other research questions, including: * What side effects may happen from taking the study drug * To see effect of cemiplimab on the tumor * How much study drug is in the blood at different times

A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients With Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC)

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Condition
Cutaneous Squamous Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Phoenix

Medical Dermatology Specialists, Phoenix, Arizona, United States, 85006

Redwood City

Stanford University School of Medicine, Redwood City, California, United States, 94063

San Diego

Therapeutics Clinical Research, San Diego, California, United States, 92123

Delray Beach

Dermatology Associates of the Palm Beaches, Delray Beach, Florida, United States, 33445

Tampa

H. Lee Moffitt Cancer Center, Tampa, Florida, United States, 33612

Atlanta

MetroDerm P.C., Atlanta, Georgia, United States, 30342

Louisville

Norton Healthcare, Louisville, Kentucky, United States, 40202

Beverly

Northeast Dermatology Associates, Beverly, Massachusetts, United States, 01915

New York

NYU Langone, New York, New York, United States, 10017

Victor

Rochester Dermatologic Surgery, Victor, New York, United States, 14564

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Regeneron Pharmaceuticals,

    Clinical Trial Management, STUDY_DIRECTOR, Regeneron Pharmaceuticals

    Study Record Dates

    2027-10-22